S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:MNOV

MediciNova Stock Forecast, Price & News

$2.22
-0.12 (-5.13%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.21
$2.40
50-Day Range
$2.22
$4.42
52-Week Range
$2.21
$10.81
Volume
133,465 shs
Average Volume
83,376 shs
Market Capitalization
$108.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.28
30 days | 90 days | 365 days | Advanced Chart
Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.


MediciNova logo

About MediciNova

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Headlines

Short Interest in MediciNova, Inc. (NASDAQ:MNOV) Declines By 17.5%
January 10, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNOV
Employees
9
Year Founded
2000

Sales & Book Value

Annual Sales
N/A
Book Value
$1.47 per share

Profitability

Net Income
$-13.85 million
Pretax Margin
-273.35%

Debt

Price-To-Earnings

Miscellaneous

Free Float
41,196,000
Market Cap
$108.88 million
Optionable
Optionable

Company Calendar

Last Earnings
11/12/2021
Today
1/22/2022
Next Earnings (Estimated)
2/17/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

859th out of 1,418 stocks

Pharmaceutical Preparations Industry

418th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












MediciNova (NASDAQ:MNOV) Frequently Asked Questions

Is MediciNova a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MediciNova stock.
View analyst ratings for MediciNova
or view top-rated stocks.

How has MediciNova's stock been impacted by COVID-19 (Coronavirus)?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MNOV shares have decreased by 32.5% and is now trading at $2.22.
View which stocks have been most impacted by COVID-19
.

Are investors shorting MediciNova?

MediciNova saw a decrease in short interest in December. As of December 15th, there was short interest totaling 1,890,000 shares, a decrease of 17.5% from the November 30th total of 2,290,000 shares. Based on an average trading volume of 496,600 shares, the days-to-cover ratio is currently 3.8 days. Approximately 4.1% of the company's stock are short sold.
View MediciNova's Short Interest
.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for MediciNova
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. The biopharmaceutical company earned $0.04 million during the quarter.
View MediciNova's earnings history
.

What price target have analysts set for MNOV?

2 brokerages have issued 12 month price objectives for MediciNova's stock. Their forecasts range from $15.00 to $15.00. On average, they expect MediciNova's stock price to reach $15.00 in the next year. This suggests a possible upside of 575.7% from the stock's current price.
View analysts' price targets for MediciNova
or view top-rated stocks among Wall Street analysts.

Who are MediciNova's key executives?

MediciNova's management team includes the following people:
  • Yuichi Iwaki, President, Chief Executive Officer & Director
  • Douglas Paulin, Chief Financial Officer
  • Federico Gaetani, Chief Scientific Officer
  • Kazuko Matsuda, Director & Chief Medical Officer
  • Geoffrey G. O'Brien, Vice President & Executive Officer

What other stocks do shareholders of MediciNova own?

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $2.22.

How much money does MediciNova make?

MediciNova has a market capitalization of $108.88 million. The biopharmaceutical company earns $-13.85 million in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does MediciNova have?

MediciNova employs 9 workers across the globe.

When was MediciNova founded?

MediciNova was founded in 2000.

What is MediciNova's official website?

The official website for MediciNova is medicinova.com.

Where are MediciNova's headquarters?

MediciNova is headquartered at 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at [email protected], or via fax at 858-404-0048.


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.